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The underlying genetic etiology of rhabdomyolysis remains elusive in a significant fraction of individuals presenting with recurrent
metabolic crises and muscle weakness. Using exome sequencing, we identified bi-allelic mutations in TANGO2 encoding transport
and Golgi organization 2 homolog (Drosophila) in 12 subjects with episodic rhabdomyolysis, hypoglycemia, hyperammonemia, and sus-
ceptibility to life-threatening cardiac tachyarrhythmias. A recurrent homozygous c.460G>A (p.Gly154Arg) mutation was found in four
unrelated individuals of Hispanic/Latino origin, and a homozygous ~34 kb deletion affecting exons 3–9 was observed in two families of
European ancestry. One individual of mixed Hispanic/European descent was found to be compound heterozygous for c.460G>A
(p.Gly154Arg) and the deletion of exons 3–9. Additionally, a homozygous exons 4–6 deletion was identified in a consanguineousMiddle
Eastern Arab family. No homozygotes have been reported for these changes in control databases. Fibroblasts derived from a subject with
the recurrent c.460G>A (p.Gly154Arg) mutation showed evidence of increased endoplasmic reticulum stress and a reduction in Golgi
volume density in comparison to control. Our results show that the c.460G>A (p.Gly154Arg) mutation and the exons 3–9 heterozygous
deletion in TANGO2 are recurrent pathogenic alleles present in the Latino/Hispanic and European populations, respectively, causing
considerable morbidity in the homozygotes in these populations.Several inherited muscle disorders have been described in
association with rhabdomyolysis with inherent failure of
energy production.1 Inborn errors of metabolism affecting
glycogenolysis and fatty acid b oxidation are known to
cause an increased susceptibility to rhabdomyolysis.
Carnitine palmitoyltransferase II deficiency (CPT II
[MIM: 600649]) is a common cause of inherited exercise-
induced myoglobinuria,2 in addition to other disorders
of fatty acid oxidation such as long chain 3-hydroxy
acyl-coenzyme A dehydrogenase (LCHAD) deficiency
(MIM: 609016)3 and very long chain acyl-CoA dehydroge-
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The Americryanodine receptor, due to RYR1 (MIM: 180901) muta-
tions, can cause muscle rigidity and rhabdomyolysis sec-
ondary to a sudden rise in free sarcoplasmic calcium
when affected individuals are exposed to general anes-
thesia.5 Recessive mutations in LPIN1 (MIM: 605518) are
yet another cause, leading to severe, recurrent, and early-
onset rhabdomyolysis, triggered by febrile illness or
exercise.6 Primary mitochondrial disorders are a rare
cause of rhabdomyolysis, reported in sporadic cases with
mutations in mitochondrial DNA genes encoding cyto-
chrome b, cytochrome c oxidase (COX) subunits, and
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Recurrent rhabdomyolysis can be fatal in severe cases,
with an associated mortality rate of 8%–10%.8,9 The mor-
tality is even greater when accompanied by acute renal
failure10 and cardiac arrhythmia due to hyperkalemia.11
Identification of genes underlying rhabdomyolysis has
significantly enhanced our understanding of its molecular
mechanisms and in several instances facilitated prevention
of recurrent episodes in susceptible individuals.12,13 How-
ever, despite considerable advances in molecular diagnos-
tics, the etiology of rhabdomyolysis remains unknown in
about half of pediatric cases.2 Whole-exome sequencing
is increasingly utilized for the diagnostic evaluation of ge-
netic disorders and is a powerful tool for molecular charac-
terization of heterogeneous clinical entities.14,15 Here we
describe variants in the transport and Golgi organization
2 homolog (Drosophila) gene, TANGO2, identified by
whole-exome sequencing in 12 subjects from 9 unrelated
families who shared clinical features of episodic muscle
weakness with recurrent rhabdomyolysis, intellectual
disability, and seizures.
All subjects were ascertained from 4,438 consecutive in-
dividuals referred to the Exome Laboratory at the Baylor
Miraca Genetics Laboratories from November 2011 to
December 2014, with the exception of proband 5, who
was primarily enrolled in the Baylor Hopkins Center for
Mendelian Genomics (BHCMG) research study. All sub-
jects were subsequently recruited in the BHCMG study
and related protocols approved by the Institutional Review
Board of Baylor College of Medicine. Informed consents
were obtained in all families. Five families were of reported
Hispanic/Latino origin, two of European ancestry, one of
mixed Hispanic/Latino/European ethnicity, and one of
Middle Eastern Arab descent.
Clinical whole-exome sequencing (WES) was completed
in the Exome Laboratory at Baylor Miraca Genetics
Laboratories and sequencing and data analyses were con-
ducted as previously described,16 targeting ~20,000 genes,
including the coding and untranslated region (UTR) exons.
Samples were also analyzed by a cSNP-array (Illumina
HumanExome-12 v1 array) for quality-control assessment
of exome data, as well as for detecting large copy-number
variants (CNVs) and regions of absence of heterozygosity
(AOH). CNVs were additionally characterized after com-
paring the normalized depth of coverage from 4,334
clinical WES samples. Exon deletions were called using a
dual normalization approach consisting of principal-
component analysis (PCA)-XHMM intermediates and
RPKM (read per kilobase per million reads) read depth
values.17 The former normalizes raw read depth values
via PCA, which were then centered by exon target on a
Z-score scale, whereas the latter was normalized at the sam-
ple level. By intersecting two orthogonal normalization
approaches (target based and sample based), we expected
an enhancement in signal and reduction in noise. In
both methods, exons with GC and low-complexity biases
were removed from the analysis. Complete homozygous
and hemizygous exon deletions were called using a strict348 The American Journal of Human Genetics 98, 347–357, Februaryfiltering criterion that must include exon target Z-scores
that are less than 2 and the RPKM is equal or near 0.
Long-range PCR (LR-PCR) reactions were performed to
amplify the predicted junction fragments in the break-
point regions in TANGO2 deletion carriers according to
the manufacturer’s specifications (Takara Bio). The junc-
tion fragment of the exons 3–9 deletion was amplified by
LR-PCR with primers (forward) 50-CGTGGAAGCAGAGG
AGGAAGGTATTTA-30 and (reverse) 50-ATAAAGAACGCG
TGTGCTCAACTGTCT-30. The junction fragment of the
exons 4–6 deletion was amplified with primers (forward)
50-TGTGCCACTGTCTTAGTTCGTTTGTGT-30 and (reverse)
50-TCTTCTGTCATCAAAAGTCCCTGGTGT-30. Breakpoint
analyses of junction fragments and haplotype studies
were conducted for TANGO2 exonic CNVs.
Subject 1, born to non-consanguineous parents of His-
panic ancestry, presented at 1 year of age with a febrile
seizure. She began to exhibit developmental regression in
the following 3 years with recurrent seizures, losing the
ability to ambulate and speak. Prior to her acute presenta-
tion at 4 years, she had a 3-day history of fever. This was
followed by a right focal seizure, apnea, and unresponsive-
ness. On hospital admission, she was noted to have myo-
globinuria with urine myoglobin of 94 ng/ml (normal
range 10–65 ng/ml), serum creatine phosphokinase
(CPK) of 205,000 U/l (normal range 75–230 U/l), elevated
aspartate aminotransferase (AST) of 1,618 U/l (normal
range 15–50 U/l), alanine aminotransferase (ALT) of
571 U/l (normal range 10–25 U/l), ammonia
of 122 mmol/l (normal range 22–48 mmol/l), and hypogly-
cemia (blood glucose 30 mg/dl; normal range 70–
110 mg/dl). She was mechanically ventilated while in the
intensive care unit. Brain magnetic resonance imaging
(MRI) showed mild diffuse atrophy of the left cerebral
hemisphere. Ophthalmology evaluation showed intermit-
tent exotropia. Echocardiogram and electrocardiogram
(ECG) were unremarkable. Metabolic studies after clinical
stabilization were normal including acylcarnitine profile,
urine organic acids, plasma/cerebrospinal fluid (CSF)
lactate levels, and serum ammonia. Physical examination
was relevant for microcephaly (FOC 47.5 cm; <5th percen-
tile for age), myopathic facies with drooling (Figure 1),
increased tone in all extremities, and brisk deep tendon re-
flexes (DTRs) throughout with positive Babinski sign.
Subject 2 of mixed Hispanic/Latino and European origin
presented at 6 months of age with metabolic acidosis
(pH of 7.0; base deficit of 20 mEq/l) and lactic acidemia
of 15 mmol/l (normal range 0.2–2.0 mmol/l). Urinalysis
showed ketonuria. Serum ammonia was mildly elevated
to 138 mmol/l. She presented with Kussmaul breathing
and was resuscitated with fluids and treated with intrave-
nous carnitine. She was noted to have a prolonged QTc in-
terval and developed premature ventricular contractions
(PVCs) transitioning into ventricular tachycardia (VT)
that was successfully treated with amiodarone. Acylcarni-
tine profile showed a primary peak of C14:1 in addition
to C14:2, C16, C18, and some hydroxy derivatives. The4, 2016
Figure 1. Nine Pedigrees with TANGO2Mutations
(A) Chromatograms are shown for families of Hispanic ancestry with the recurrent c.460G>A (p.Gly154Arg) mutation and c.605þ1G>A
mutation.
(B) Early childhood photos of subjects 1 and 3.
(C) Long-range PCR data confirm the exons 3–9 deletion in carrier parents and in subjects of European descent. Data are also shown for
the consanguineous family 9 of Middle Eastern origin, having a smaller exons 4–6 deletion. In both gel pictures, the upper band repre-
sents the presence of the breakpoint junction for the deletion and the lower band (1 kb) represents the non-deleted allele.
(D) Breakpoint junction sequences for the exons 3–9 deletion and the exons 4–6 deletion are depicted under each gel picture, respec-
tively. The breakpoint junction sequence is aligned with reference sequences with the red/blue color change indicating transition be-
tween proximal and distal reference sequences.C14:1 completely normalized after intravenous glucose
therapy. Etiologic evaluations, including DNA sequencing
of ACADVL for VLCAD deficiency, muscle histopathology,
quantitative mtDNA studies in muscle, and mitochondrial
genome sequencing for common point mutations and de-
letions, were normal. She began walking unassisted around
15 months of age and presented to the hospital again at
16months of age with weakness and gait abnormality after
a 1-week history of sore throat and vomiting. She was nor-
moglycemic, with CPK of 1,126 U/l, ASTof 158 U/L, mildly
elevated ammonia of 71 mmol/l, and lactate of 7.0 mmol/l.
After resolution of this episode, she presented again at 5
years of age after a viral illness; this time with lethargy,
lower extremity weakness, myoglobinuria, CPK of
287,230 U/l, hypoglycemia (glucose of 17 mg/dl), and
elevated transaminases (AST of 7,618 U/l and ALT of
2,564 U/l). Her lactate was 2.0 mmol/l. Aldolase level wasThe Americ595 U/l (normal range 2.7–8.8 U/l). Renal function tests re-
mained stable throughout admission. Evaluation after res-
olution of her acute episode showed myopathic face with
drooling, dysarthric speech, and ataxia.
Subject 3 was 27 years old, was of Hispanic/Latino
origin, and had a history of multiple episodes of acute
altered mental status, elevated CPK, increased transami-
nases, and ketotic hypoglycemia. Her first episode was at
5 months of age, when she arrived comatose in the
emergency room with metabolic acidosis. Her CPK was
elevated at 8,000 U/l. She had at least two additional epi-
sodes of rhabdomyolysis, with highest reported CPK of
22,000 U/l. During her most severe presentation at age
24 years, she had a concurrent urinary tract infection.
During her subsequent hospitalization, she was noted to
have torsade de pointes. Her clinical course was compli-
cated by respiratory and multiorgan failure. She was notedan Journal of Human Genetics 98, 347–357, February 4, 2016 349
Table 1. Clinical Features of Individuals with Bi-allelic TANGO2 Mutations
Family 1 Family 2 Family 3 Family 4 Family 5
Subject 1 Subject2 Subject 3 Subject 4 Subject 5
II-1 II-1 II-1 II-1 II-1
Age at first
presentation
4 years 6 months 5 months 8 years 7 years
Current age 6 years 6 years 27 years 14 years 17 years
Gender female female female male female
Ethnicity Hispanic Hispanic/European Hispanic Hispanic Hispanic
Parental relationship non-consanguineous non-consanguineous non-consanguineous non-consanguineous non-consanguineous
Nucleotide change c.460G>A c.460G>A c.460G>A c.460G>A c.460G>A
Amino acid change p.Gly154Arg p.Gly154Arg p.Gly154Arg p.Gly154Arg p.Gly154Arg
Intragenic deletion – exons 3–9 del – – –
Mutation homozygous compound
heterozygous
homozygous homozygous homozygous
Highest CPK 205,000 U/l 287,230 U/l 22,000 U/l 16,674 U/l 60,000 U/l
Rhabdomyolysis yes yes yes yes yes
Glucose hypoglycemia hypoglycemia hypoglycemia normoglycemia hypoglycemia
Ammonia [ [ normal [ ND
Lactate ND [ [ normal [
Seizures yes no yes yes yes
Intellectual disability yes yes yes yes yes
ECG/arrhythmia normal prolonged QTc interval,
ventricular tachycardia
ventricular tachycardia
requiring ICD
placement
prolonged QTc interval,
Brugada pattern
prolonged QTc interval,
torsade de pointes,
requiring ICD placement
Abbreviations are as follows: ND, not determined; ICD, automatic implantable cardioverter-defibrillator.
aMonozygotic twin of subject 11 had a very similar presentation, but passed away at 7 years of age before molecular confirmation could be obtained.to have multiple episodes of ventricular fibrillation,
requiring placement of an automatic implantable cardi-
overter-defibrillator (ICD). She also was maintained on
Nadolol therapy. Her additional diagnoses were epilepsy,
bilateral sensorineural hearing loss, and intellectual
disability. Muscle biopsy showed atrophic muscle fibers,
suggestive of neuropathic process. She was able to ambu-
late and communicate with short phrases. Her physical
examination was significant for height and weight
below the 5th percentile for age (weight 42.9 kg, height
147 cm), head circumference below 5th percentile for age
(51.4 cm), myopathic facies with persistent drooling, and
wide-based gait.
Subject 4, also of Hispanic/Latino origin, was reported
to have uncoordinated gait after 2 years of age. He had
a diagnosis of intellectual disability. He presented at 8
years of age with an acute episode of disorientation, ataxic
gait, weakness in lower extremities, and dysarthria. His
lactate and glucose were found to be normal; ammonia
was elevated to 111 mmol/l. CPK was elevated to350 The American Journal of Human Genetics 98, 347–357, February16,674 U/l. Urine was negative for myoglobin. TSH level
was increased to 30.8 mIU/ml (range 0.32–5.00 mIU/ml),
T3 was 166 ng/dl (range 90–260 ng/dl), and T4 was
5.2 mg/dl (range 6.4–13.3 mg/dl). Urine organic acids
were normal. He also developed a prolonged QTc interval
(579 ms) during hospitalization. A Brugada pattern was
noted on one ECG (Figure S1). Muscle biopsy showed
normal respiratory chain studies. Mitochondrial genome
sequencing for common point mutations and deletions
were normal. Brain MRI study showed mild cerebellar vol-
ume loss. His speech continued to be slurred when evalu-
ated at 12 years. His physical examination was significant
for myopathic facies, brisk DTRs with sustained clonus,
and impaired gait.
The clinical description of the remaining eight individ-
uals is provided in the Supplemental Data and summa-
rized in Tables 1 and S1. Ten out of 12 subjects presented
with acute rhabdomyolysis, their first episode between
5 months and 8 years of age, with highest CPK levels
ranging from 16,674–287,230 U/l. Neurodevelopmental4, 2016
Family 6 Family 7 Family 8 Family 8 Family 8 Family 9 Family 9
Subject 6 Subject 7 Subject 8 Subject 9 Subject 10 Subject 11 Subject 12
II-1 III-2 II-1 II-2 II-3 II-2a II-3
1 year 18 months 9 months 1 year 3.5 months 2 years 4 years
3 years 9 years deceased (2 years) deceased (22 months) 11 months 11 years 8 years
male male female dizygotic twin male dizygotic twin female male monozygotic
twin
male
Hispanic European European European European Arab Arab
consanguineous non-consanguineous non-consanguineous non-consanguineous non-consanguineous consanguineous consanguineous
c.605þ1G>A – – – – – –
– – – – – – –
– exons 3–9 del exons 3–9 del exons 3–9 del exons 3–9 del exons 4–6 del exons 4–6 del
homozygous homozygous homozygous homozygous homozygous homozygous homozygous
103 U/l 258,000 U/l 97,500 U/l 17,900 U/l 248 U/l >100,000 U/l 54,258 U/l
no yes yes yes no yes yes
hypoglycemia hypoglycemia hypoglycemia hypoglycemia hypoglycemia normoglycemia normoglycemia
[ [ normal [ [ [ [
[ [ [ [ [ [ [
no yes yes yes no yes yes
yes yes yes yes yes yes yes
ND normal prolonged QTc
interval
bradycardia and
premature ventricular
contractions and
junctional rhythm;
prolonged QTc
interval
normal normal prolonged QTc
interval, torsade de
pointes progressing
to ventricular
tachycardia,
requiring ICD
placementproblems were observed in 100% of the affected individ-
uals by early childhood, with muscle weakness, gait ab-
normality, or poor coordination reported in most individ-
uals prior to the acute presentation of myoglobinuria.
Seizures were present in 9/12 subjects. The acute clinical
presentation ranged from profound muscle weakness,
ataxia, and/or disorientation to a comatose state
frequently precipitated by an acute illness. In subject 7,
rhabdomyolysis and hypoglycemia occurred after imple-
mentation of a ketogenic diet for the treatment of sei-
zures. During these metabolic crises, hypoglycemia (range
6–30 mg/dl), hyperlactacidemia (range 2–17 mm/l), and
mild hyperammonemia (range 71–138 mmol/l) were
repeatedly observed. Elevated transaminases were also
noted, indicative of muscle injury. Acylcarnitine profiles
during acute episodes showed elevated C14:1 in at least
three individuals (subjects 2, 6, and 10); subject 10 addi-
tionally had elevated C10 species during the acute
episode. Subject 11 had elevated propionyl-carnitine
(C3) and C10 species on evaluation. Life-threatening car-
diac tachyarrhythmia presented as torsade de pointes orThe Americventricular tachycardia in 4/12 (33%) individuals. Inter-
mittent prolonged QTc interval ranging from 462 to
579 ms was seen in 6/12 (50%) subjects (Figure S1), which
often reverted to normal between episodes. Brugada
pattern was observed only in subject 4 (Figure S1). Sub-
jects 3, 5, and 12 required placement of an ICD as prophy-
laxis for their increased propensity toward serious cardiac
arrhythmias. Metabolic abnormalities typically normal-
ized outside the critical period of crises in these individ-
uals, although some continued with mildly elevated
CPK levels. Mitochondrial studies (both molecular and
biochemical, including electron transport chain analysis)
and muscle biopsies were essentially normal, although
mild histological abnormalities such as acute neurogenic
atrophy were observed in a minority. Structural brain
abnormalities were frequently present (7/10), mostly
reflective of varying degrees of cerebral atrophy or volume
loss. Gait disturbances, dysarthria, and myopathic facies
were observed in most individuals outside the crisis epi-
sodes. Hypothyroidism was diagnosed in 4/12 subjects.
Two young subjects in family 8 died at 2 years of age.an Journal of Human Genetics 98, 347–357, February 4, 2016 351
Figure 2. TANGO2-Specific CNV Detec-
tion from the Clinical Exome Data and
the Spectrum of Mutations in Nine Unre-
lated Families
(A) Target Z-score of PCA-normalized read
depths for exon targets of TANGO2. Sam-
ples with heterozygous or homozygous de-
letions are shown in various colors on the
left and right, respectively. All samples
with deletions are depicted with read
depths (RD) well below the other samples
(gray) (n ¼ 4,334 total samples). Samples
with homozygous deletions have RD lower
than heterozygous deletions and contain
exons with reads per kilobase of transcript
per million mapped reads (RPKM) values
equal or near 0. Individuals with exons
3–9 homozygous deletions (~34 kb) and
heterozygous deletions are shown in this
figure, as subjects 2, 7, and 8. Subject 11
with the smaller exons 4–6 homozygous
deletion is represented in red.
(B) TANGO2 transcript (GenBank: NM_
152906.5) with mutations and deletions
found in our study cohort. Light blue
regions represent the coding exons,
dark blue regions represent 50 and 30
untranslated regions, and black bars
represent introns (not to scale). The loca-
tions of c.460G>A (p.Gly154Arg) and
c.605þ1G>A variants are shown. The
~34 kb deletion that encompasses exons
3 through 9 and the ~9 kb deletion that
includes exons 4 through 6 are shown.The oldest individual in our study is currently alive at
27 years of age.
Prior to clinical WES, the differential diagnoses for
many of these individuals included VLCAD deficiency
(MIM: 201475), acute recurrent myoglobinuria (MIM:
268200), carnitine palmitoyltransferase II deficiency
(MIM: 600649), glutaric acidemia IIB (MIM: 231680), and
mitochondrial disorders. Nevertheless, after WES, the
sequence analyses of the associated genes, ACADVL
(MIM: 609575), LPIN1 (MIM: 605518), CPT2 (MIM:
600650), and ETFB (MIM: 130410), did not identify any
contributing variants. Although no deleterious mutations
were found in the known nuclear-encoded mitochondrial
genes or in other genes related to the described phenotype
in these subjects, a recurrent apparently homozygous
variant c.460G>A (p.Gly154Arg) in exon 7 of TANGO2
(GenBank: NM_152906.5 transcript) was identified in
five out of nine unrelated families (Figures 1 and 2). Four
of these subjects (1, 3, 4, and 5) were of Hispanic/Latino
origin and subject 2 was of mixed Latino/European
ancestry. Sanger sequencing confirmed the homozygous
variant in probands 1, 3, 4, and 5 and validated the pres-352 The American Journal of Human Genetics 98, 347–357, February 4, 2016ence of heterozygous alleles in each
parent for probands 3, 4, and 5. For
subject 1, the mother was confirmed
to be heterozygous and the father
was unavailable for further studies.
Coding single-nucleotide polymorphism (cSNP) data
showed no evidence of deletion or uniparental isodisomy
affecting the region, strongly suggesting that the proband
carried two copies of the c.460G>A (p.Gly154Arg) allele,
one inherited from each parent.
For subject 2, only the maternal sample was noted to
be heterozygous for the c.460G>A (p.Gly154Arg) variant
the father of European ancestry was found to have
normal sequencing results (Figure 1). Considering that a
cryptic copy-number loss within TANGO2 could poten-
tially elucidate the observed segregation results in this
family, we compared the normalized depth of coverage
from more than 4,000 clinical WES samples with that
from individual subjects and identified an apparent intra-
genic deletion of exons 3–9 (~34 kb) in subject 2
(Figure 2A). Long-range PCR validated the presence of
the heterozygous deletion, inherited from her father, con-
firming that she was compound heterozygous for the
TANGO2 mutation. We subsequently identified the
same ~34 kb deletion as homozygous alleles in two addi-
tional families of European descent (families 7 and 8)
(Figures 1 and 2).
Of the two families with known consanguinity, proband
6 (family 6) was found to have a homozygous splice site
variant in intron 7, c.605þ1G>A, and subjects 11 and 12
(family 9) were shown to be homozygous for a smaller
intragenic deletion CNV (~9 kb), which encompassed
exons 4–6 of TANGO2 (Figures 1 and 2). We then investi-
gated whether the findings in subjects with the recurrent
c.460G>A (p.Gly154Arg) homozygous mutation and
exons 3–9 deletion were potentially due to undetermined
consanguinity. The cSNP array data and exome data did
not detect any absence of heterozygosity (AOH) regions
greater than 5 Mb in subjects from families 1, 3, 4, 5, 7,
or 8, all of whomwere homozygous for either the recurrent
c.460G>A (p.Gly154Arg) mutation or the ~34 kb CNV
deletion; conversely, the total AOH region in proband 6
from family 6 was about 46.3 Mb, including 9.7 Mb of
AOH encompassing TANGO2, while the total AOH in sub-
jects 11 and 12 from family 9 was ~212.5 Mb, including
13.3 Mb of AOH encompassing TANGO2. Our genomic
data support the reported consanguineous relationships
in families 6 and 9.
The analysis of the ~350 nt region surrounding the
breakpoint junctions in families 2, 7, and 8 with the exons
3–9 deletion showed 20 variants differing from the refer-
ence genome (Figure S2), including 12 variants not
observed in the public databases. These variants were
shared by all heterozygous parents and subjects carrying
the deletion, implicating this as a likely single ancestral
variant in the European population. For individuals with
the c.460G>A (p.Gly154Arg) mutation, a lack of common
segregating variants on the cSNP array in the immediate
500 kb region across TANGO2 obscured the identification
of a common ancestral haplotype; however, subjects 1, 3,
and 4 shared the same homozygous haplotype over a
longer 1.4 Mb region that traverses TANGO2 and includes
23 segregating variants (Figure S3). These data suggest
a distant shared ancestry among these families. This
extended haplotype was not observed in subject 5, how-
ever, suggesting either recurrent mutation at this CpG
site or that there has still been sufficient time since the
variant arose for the effect of recombination on the orig-
inal ancestral haplotype to be observed. A higher density
of segregating markers in the intervening region could
potentially help to resolve this question.
The minor allele frequency (MAF) of the c.460G>A
(p.Gly154Arg) allele in control subjects has been reported
to be 0.26% (14/5,306 alleles) in the Hispanic/Latino pop-
ulation, 0.0026% (1/38,266 alleles) in Europeans, and 0%
in African Americans, with an overall frequency of 0.02%
(16/69,044 alleles) in all populations in the database
from the Exome Aggregation Consortium (ExAC; n ¼
61,486 exomes; accessed February 2015). No homozygotes
have been reported for this variant in this database or
other databases including the 1000 Genomes (release
20110521), dbSNP134, and NHLBI GO Exome Sequencing
Project (accessed February 2015). The rare c.605þ1G>A
splice site mutation has been reported in ExAC with aThe AmericMAF of 0.25% (1/396 alleles) in the Latino population
and an overall MAF of 0.03% (6/18,796 alleles, no homozy-
gotes found) in all populations.
We then investigated the frequency of the exons 3–9
deletion of TANGO2 in large population-based studies
and interrogated whether homozygotes were identified in
these studies. Shaikh et al.18 reported heterozygous loss
affecting the same region as the ~34 kb deletion in
3/1,320 white Europeans, with an allele frequency of
0.11% (3/2,640 alleles). Similarly, for the same deletion,
Coe et al.19 reported a population frequency of 17/
13,347 samples (MAF 0.06%, 17/26,694 alleles), including
8,822 of presumed European ethnicity (ARIC and Well-
come Trust Case Control Consortium, WTCCC2 project
samples from National Blood Donors). Ethnicity was avail-
able for only 11 of the 17 individuals with the heterozy-
gous deletion, and all the 11 individuals were of European
origin, corresponding to a European-specific MAF of at
least 0.062% (11/17,644 alleles). No homozygous deletions
were reported in these large control datasets. The ~9 kb
deletion identified from subjects of Arab origin in this
study was not identified in the public control datasets.
The gross deletions and the c.605þ1G>A mutation
affecting the canonical splice donor site at the exon 7/
intron 7 boundary of TANGO2 (GenBank: NM_152906.5
transcript, total nine exons) were interpreted as loss-of-
function (LOF) pathogenic variants based on variant inter-
pretation guidelines from the American College of Medical
Genetics and Genomics (ACMG).20 The c.460G>A
(p.Gly154Arg) substitution affects a glycine residue that
is highly conserved in species from fish to primates
(Figure S4). The substitution of glycine to arginine at this
site is predicted to alter the tertiary structure and probably
be damaging by in silico prediction programs (Figure S5).
The function of TANGO2 is unknown; however, in pre-
vious studies, depletion in Drosophila S2 tissue culture cells
was observed to cause fusion of the Golgi with the ER.21
Because of this known association, we sought to evaluate
the structure of the Golgi apparatus in the fibroblasts
from subject 5 with homozygous c.460G>A (p.Gly154Arg)
TANGO2 mutation. Evaluation of Golgi apparatus and
TANGO2 were performed by fluorescence microscopy as
previously described.22 Subject fibroblasts were allowed
to adhere to poly-L-lysine-coated slides overnight at
37C, 5% CO2, which were then washed in PBS and per-
meabilized with Cytofix/Cytoperm reagent (BD). Cells
were then stained with 1 mg/ml polyclonal rabbit IgG
aTANGO2 (Abcam) for 1 hr. Cells were washed and then
stained with a-Rabbit Alexa Fluor-647 and WGA Alexa
Fluor-488 for 30 min. Slides were mounted with prolong
gold containing DAPI and allowed to cure overnight. Slides
were then visualized with a Leica SP8 TCS STED micro-
scope (Leica Microsystems).22 In brief, excitation was per-
formed using a tunable white light laser and emission
was detected by HyD detectors. Settings were adjusted
based on single-color controls and independent channels
were acquired sequentially to limit fluorescencean Journal of Human Genetics 98, 347–357, February 4, 2016 353
Figure 3. c.460G>A (p.Gly154Arg) TANGO2 Mutant Cells Show Decreased ER and Golgi Area and Increased ER Stress
(A) Fibroblasts from healthy control and subject 5 were intracellularly stained with wheat germ agglutinin (WGA), a marker of trans
Golgi and anti-TANGO2. The volumes of the resulting structures of both WGA (34.4 5 7.5 mm3 p.Gly154Arg, 2465 60 mm3 control,
p < 0.01) and TANGO2 (34.95 7.8 mm3 p.Gly154Arg, 2945 55 mm3 control, p < 0.01) were found to be significantly lower in the sub-
ject fibroblasts by Student’s t test.
(B) BLCLs fromhealthy control and subject 4 were intracellularly stainedwithWGA and anti-GM130. The area of the resulting structures
was found to be significantly smaller in affected BLCLs than from healthy controls (Student’s t test p < 0.0001) for both WGA and
GM130.
(C) Fibroblasts from healthy control and subject 5 were intracellularly stained with ER Tracker red and anti-BiP and treated either with
DMSO or Brefeldin A (BFA), an inhibitor of the ER Ca2þ ATPase. The volume of the resulting structure of the ER was found to be lower in
the subject fibroblasts by Student’s t test (14.4 5 1.2 mm2 p.Gly154Arg, 65 5 3.5 mm2 control, p < 0.0001), whereas the level of BiP
within the ER was significantly increased when normalized to ER after treatment with brefeldin A (1.5 5 0.4 mm2 p.Gly154Arg,
0.45 0.05 mm2 control, p < 0.0001).contamination. Microscopy images were analyzed with
Volocity software. Intensity of signal was thresholded
based on 3 SDs above the mean intensity. Objects less
than 0.1 mm3 were excluded. All values were exported to
GraphPad Prism v.6 for graphing and statistical analysis.
Statistical tests were performed with the Student’s t test.
Differences were considered significant at a p < 0.05. ER
was identified by staining with ER tracker red (Life Tech-
nologies) and Golgi was evaluated by intracellular staining
with wheat germ agglutinin (WGA) conjugated with354 The American Journal of Human Genetics 98, 347–357, FebruaryAlexa-488 (Molecular Probes). Images were then acquired
on Amnis Image Stream Mark II (EMD Millipore) and
analyzed with IDEAS software package. Both ER (14.4 5
1.2 mm2 p.Gly154Arg, 65 5 3.5 mm2 control, p < 0.0001)
and Golgi (34.4 5 7.5 mm3 p.Gly154Arg, 246 5 60 mm3
control, p < 0.01) showed decreased size in the mutant fi-
broblasts, when compared to control (Figures 3A and 3C).
The combined data shown are the mean 5 SD.
We then used EBV-transformed B-lymphoblastoid cell
lines (BLCLs) from another individual, subject 4 with4, 2016
homozygous c.460G>A (p.Gly154Arg) mutation, and eval-
uated the Golgi by intracellular staining withWGA, as well
as cis Golgi marker, anti-GM130 antibody (Abcam cat#
ab31561, RRID: AB_2115328). The area of the resulting
structures was found to be significantly smaller in
subject-derived BLCLs than from healthy control (WGA
staining: control 5.76 5 1.2 mm3 [n ¼ 74], p.Gly154Arg
0.35 5 0.1 mm3 [n ¼ 190]; GM130 staining: control
24.4 5 2.3 mm3 [n ¼ 74], p.Gly154Arg 12.2 5 1.2 mm3
[n ¼ 190], Student’s t test p < 0.0001) (Figure 3B). Using
anti-TANGO2 (anti-C22orf25) antibody (Abcam cat#
ab87576, RRID: AB_2040650), the TANGO2 volume was
found to be reduced in the subject fibroblasts compared
to controls (34.9 5 7.8 mm3 p.Gly154Arg, 294 5 55 mm3
control; p < 0.01) (Figure 3A).
Given the role of the Golgi in vesicular trafficking and
the delicate balance that must be maintained, we evalu-
ated the level of ER stress in the affected fibroblast tissue
in subject 5. To induce ER stress, the fibroblasts were
treated with low levels of Brefeldin A (BFA), an inhibitor
of the ER Ca2þ ATPase, and the expression of ER stress
sensor, immunoglobulin heavy chain binding protein
(BiP), was measured by staining with rabbit polyclonal
anti BiP (Anti-GRP78 BiP antibody; Abcam cat# ab21685,
RRID: AB_2119834) followed with anti-rabbit IgG Alexa
488 (Life Technologies). We found that whereas ER-associ-
ated BiP levels were similar in subject-derived fibroblasts
and control (0.04 5 0.02 mm2 p.Gly154Arg, 0.1 5
0.02 mm2 control), when treated with brefeldin A, the BiP
levels were increased in the affected cells (1.5 5 0.4 mm2
p.Gly154Arg normalized to ER, 0.4 5 0.05 mm2 control;
p < 0.0001) (Figure 3C). Taken together, these data suggest
that disruptions in TANGO2 result in an imbalance in the
vesicular pathway.
We describe nine families with a Mendelian disorder
characterized by recurrent rhabdomyolysis and susceptibil-
ity to cardiac arrhythmias. The various homozygous and
compound heterozygous genetic alterations including
both point mutations (SNVs) and copy-number variants
(multi-exon deletion CNVs ranging from 9 to 34 kb in
size) in TANGO2 in these unrelated families support a
common etiology of a progressive neurologic disorder
characterized by intellectual disability and intermittent
rhabdomyolysis. The overlap in phenotype with disorders
of fatty acid oxidation and mitochondrial energy meta-
bolism with associated lactic acidosis and hypoglycemia
led to extensive relevant biochemical and molecular
studies in several of these children. Sudden tachyarrhyth-
mias are known to occur with disturbance of fatty acid
oxidation even in the absence of cardiomyopathy; this is
thought to be secondary to the accumulation of arrhyth-
mogenic intermediary metabolites of fatty acids, such as
long-chain acylcarnitines.23,24 The basis of arrhythmia in
individuals with TANGO2 mutation is unknown at pre-
sent. It is also unclear whether this phenotype is integral
to the functions of TANGO2 in cardiac tissue or a conse-
quence of acute myocyte breakdown with rhabdomyoly-The Americsis. It is important to note that 2 of the 12 individuals (sub-
jects 8 and 9) and the monozygotic twin of subject 11
(family 9) died during acute crises, underscoring the need
for urgent molecular diagnosis of this life-threatening
disorder.
Transport and Golgi organization (TANGO) proteins,
first discovered in RNA-mediated interference screens in
Drosophila, play an important role in cargo loading of
newly synthesized secretory proteins in the ER. TANGO1,
a transmembrane receptor ER protein, binds to collagen
VII in the lumen of the ER, facilitating its loading into
coat protein complex II (COPII) carriers on the cytoplasmic
sites.25,26 Much less is known about TANGO2, found to
be localized to the Golgi and cytoplasm. The gene is
within the critical region of the 22q11.2 locus, commonly
deleted in the DiGeorge/Velocardiofacial syndrome (MIM:
188400). The encoded protein has a highly conserved
DUF833 domain, of unknown function. Previous studies
have shown that depletion of Tango2 causes fusion of
the Golgi with the ER in Drosophila.21 We hypothesized
that perturbed vesicular Golgi/ER transport from TANGO2
mutations could result in similar ER and Golgi disruption
and increased ER stress contributing to diseasemechanism.
We found that the size of Golgi was decreased, both in the
fibroblasts derived from subject 5 and lymphoblasts origi-
nating from subject 4. We also found that the BiP levels
were enhanced in the mutant fibroblasts with higher
expressionwhen normalized to ER, indicating an increased
level of ER stress. It remains to be seen whether the Golgi
organization is affected in other individuals with the
deletion genotype. The functional analysis in these sub-
jects provide a framework for future experiments in indi-
viduals with multi-exonic TANGO2 deletions. Golgi frag-
mentation is known to be a common hallmark of
neurodegenerative diseases including Parkinson, Alz-
heimer,27 and amyotrophic lateral sclerosis (ALS).28
Further studies would ultimately define whether ER-Golgi
trafficking is inhibited with protein aggregation, as
observed in these neurodegenerative diseases.
Our study shows that the c.460G>A (p.Gly154Arg) allele
in TANGO2 is enriched in the Hispanic-Latino population
and can cause significant morbidity in homozygotes in
this population. This mutation is exclusively found in
the heterozygous state in controls, with a minor allele
frequency of 0.26% in the Hispanic/Latino population.
Hardy-Weinberg expectations for homozygotes for the
mutant allele in the Hispanic/Latino population would
be approximately 1 in every 150,000 individuals. The allele
frequency of the exons 3–9 deletion from previous studies,
predominantly including Europeans,18,29 is 0.06%–0.1%.
On the basis of the estimated frequency of this deletion
allele in heterozygous state, homozygosity would be ex-
pected to occur (at most) in 1 in every 1,000,000 individ-
uals (given Hardy-Weinberg expectations). Our study
shows that the exons 3–9 deletion of TANGO2 occurs on
a common genetic background with shared haplotype in
the European deletion carriers. The disease burden due toan Journal of Human Genetics 98, 347–357, February 4, 2016 355
exon-specific deletion in non-Europeans remains to be
ascertained.
Accumulating evidence has revealed disease susceptibil-
ity associated with low-frequency variants that are often
specific to populations of distinct ancestries.30,31 This
was initially highlighted with the discovery of low-
frequency missense variants in PCSK9 (MIM: 607786)
associated with reduced low-density lipoprotein (LDL)
cholesterol levels and reduced coronary heart disease risk
in distinct populations.32 In our previous study, we re-
ported a single-exon deletion copy-number variant within
TM4SF20 (MIM: 615404) enriched in the Southeast Asian
population (allele frequency of ~1%) causing increased sus-
ceptibility to early language delay and cerebral white mat-
ter hyperintensities (MIM: 615432).33 The complex admix-
ture of persons of Hispanic ancestry makes it difficult to
invoke a specific population genetic mechanism for the
commonality of the c.460G>A (p.Gly154Arg) allele from
the available data, although a founding event seems
more likely than other inferences. Advances in sequencing
technology have led to a substantial improvement in the
annotation of genomic variants among global population
samples; thus, our understanding of the impact of low-fre-
quency population-specific deleterious alleles of different
variant types (SNV or CNV) is only beginning to take
shape. This is particularly true for population-specific al-
leles deleterious only in a homozygous state, such as
observed for the c.460G>A (p.Gly154Arg) mutation and
exons 3–9 TANGO2 deletion in the Hispanic/Latino and
European populations, respectively. Understanding the
population genetic events driving such observations in
their respective populations represents a fertile area for
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